Similarly, elevated YAP1 levels in tubule cells have been previously reported, and inhibiting the YAP1 activity through pharmacological or genetic means has shown promising results in ameliorating renal fibrosis, inflammation, and oxidative stress in experimental type 1 diabetes-related DKD models [26,48]. The gene discussed is YAP1; the disease is diabetic kidney disease.